Média

Onxeo Launches Capital Increase

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), a biopharmaceutical company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the launch of a capital increase of new ordinary shares without preferential subscription rights reserved for the  category of investors described below. The…read more →

Onxeo Announces First Outcomes of Livatag® Preclinical Plan

Livatag® Nanoformulation Leads to Increased Exposure and Preferential Affinity for Liver, Supporting Current Relive Phase III Study Rationale Demonstrates Enhanced Effect in Combination with Immunotherapy  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced data from 2 in vivo studies of the Livatag® preclinical plan…read more →

Onxeo to Present at the 18th Annual Rodman and Renshaw Global Investment Conference in New York

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced that Company management is scheduled to present at the 18th Annual Rodman & Renshaw Global Investment Conference, being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY. During the presentation,…read more →

Combination of AsiDNA and PARP Inhibitors Demonstrates Synergistic Effect, Bypasses Genetic Restriction

Preclinical Research Published in Clinical Cancer Research Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced results from a preclinical study demonstrating that the synergistic effect of its lead signal-interfering DNA product candidate AsiDNA™ in combination with various products in the PARP (PolyADP-Ribose Polymerase) inhibitor…read more →

Onxeo Reports First-Half 2016 Business Update and Consolidated Financials

- Expansion of orphan oncology pipeline through acquisition of DNA Therapeutics and lead compound AsiDNATM - Important development milestones on existing assets: Livatag® Phase III trial in HCC: 80% of patients randomized First development steps of the new oral formulation of Beleodaq® - Board reinforced with high-profile pharma business and scientific experts and establishment of US subsidiary in New York City - €19.6M…read more →

Onxeo Signs Exclusive License Agreement with Pint Pharma for the Commercialization of Beleodaq® in PTCL in South America

Agreement covering seven South American countries Onxeo to receive upfront payment, regulatory and commercial milestones, and sales royalties for a total deal value greater than USD 20 million Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapeutics, today announced it has entered into an exclusive license agreement…read more →

Onxeo collaborates with the Royal College of Surgeons in Ireland for research program on Beleodaq® derivatives // DANISH TRANSLATION: Onxeo samarbejder med Royal College of Surgeons i Irland om forskningsprogram vedrørende derivater af Beleodaq®

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced a collaboration with the Royal College of Surgeons in Ireland (RCSI) for a discovery-stage program on the derivatives of belinostat (Beleodaq®), a histone deacetylase (HDAC) inhibitor. This new collaboration program aims…read more →

Onxeo receives USPTO Notice of Allowance for key AsiDNA™ patent, extending IP protection in the U.S. until 2031 // DANISH TRANSLATION: Onxeo modtager “Notice of Allowance” fra de amerikanske patentmyndigheder for det primære AsiDNA™ patent, hvilket forlænger patentbeskyttelsen i USA indtil 2031

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Products, including AsiDNA (signal interfering DNA), protected until 2031 with potential extension to 2036 Onxeo’s intellectual property for DNA repair signal interfering technology and products protected by 8 patent families worldwide  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO), an innovative company specialized in the development of orphan oncology therapies, today…read more →

Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA // DANISH TRANSLATION: Onxeo offentliggør udviklingsplan for det innovative signal-interfererende DNA-produkt AsiDNA

NB! FOR DANISH TRANSLATION, SCROLL DOWN. Near- and mid term expected milestones  Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, Nasdaq Copenhagen: ONXEO, “Onxeo” or ”the Company”), an innovative company specializing in the development of orphan oncology therapeutics, today announced its plan for further development of AsiDNA, its first-in-class signal interfering DNA molecule which breaks the cycle of tumor DNA…read more →